APX 343A
Alternative Names: APX-343ALatest Information Update: 28 Jan 2026
At a glance
- Originator AptaBio Therapeutics
- Class Antineoplastics; Immunotherapies
- Mechanism of Action CYBB protein inhibitors; NOX1 protein inhibitors; NOX4 protein inhibitors
-
Orphan Drug Status
Yes - Solid tumours
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 24 Nov 2025 AptaBio has patent protection for APX 343A in Europe, the United States, Japan, and Australia .
- 24 Oct 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Combination therapy) in South Korea (PO) (NCT07123415)
- 24 Oct 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Monotherapy) in South Korea (PO) (NCT07123415)